Basit öğe kaydını göster

A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

dc.contributor.authorHamza, R
dc.contributor.authorFerhanoglu, B
dc.contributor.authorKhalid, HM
dc.contributor.authorIntragumtornchai, T
dc.contributor.authorKim, SW
dc.contributor.authorKim, SY
dc.contributor.authorKoc, H
dc.contributor.authorKumar, L
dc.contributor.authorKumar, R
dc.contributor.authorLei, KI
dc.contributor.authorLekhakula, A
dc.contributor.authorMuthalib, A
dc.contributor.authorPatel, M
dc.contributor.authorPoovalingam, VP
dc.contributor.authorPrayoonwiwat, W
dc.contributor.authorRana, F
dc.contributor.authorReksodiputro, AH
dc.contributor.authorRuff, P
dc.contributor.authorSagar, TG
dc.contributor.authorSchwarer, AP
dc.contributor.authorSong, HS
dc.contributor.authorSuh, CW
dc.contributor.authorSuharti, C
dc.contributor.authorSupindiman, I
dc.contributor.authorTee, GY
dc.contributor.authorThamprasit, T
dc.contributor.authorVillalon, AH
dc.contributor.authorWickham, NR
dc.contributor.authorWong, JE
dc.contributor.authorYalcin, A
dc.contributor.authorJootar, S
dc.contributor.authorGiles, FJ
dc.contributor.authorShan, JQ
dc.contributor.authorAdvani, SH
dc.contributor.authorAkan, H
dc.contributor.authorAydogdu, I
dc.contributor.authorAziz, Z
dc.contributor.authorAzim, HA
dc.contributor.authorBapsy, PP
dc.contributor.authorBuyukkececi, F
dc.contributor.authorChaimongkol, B
dc.contributor.authorChen, PM
dc.contributor.authorCheong, SK
dc.date.accessioned2021-03-04T11:48:47Z
dc.date.available2021-03-04T11:48:47Z
dc.identifier.citationGiles F., Shan J., Advani S., Akan H., Aydogdu I., Aziz Z., Azim H., Bapsy P., Buyukkececi F., Chaimongkol B., et al., "A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study", LEUKEMIA & LYMPHOMA, cilt.40, ss.95-103, 2000
dc.identifier.issn1042-8194
dc.identifier.othervv_1032021
dc.identifier.otherav_7436aea2-5333-49c8-99d5-372537308299
dc.identifier.urihttp://hdl.handle.net/20.500.12627/79872
dc.identifier.urihttps://doi.org/10.3109/10428190009054885
dc.description.abstractThe addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL.
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHEMATOLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.titleA prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study
dc.typeMakale
dc.relation.journalLEUKEMIA & LYMPHOMA
dc.contributor.department, ,
dc.identifier.volume40
dc.identifier.startpage95
dc.identifier.endpage103
dc.contributor.firstauthorID126964


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster